Gynaecological cancers


Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

Banerjee, et al.


The addition of ASA to BEV+ATE did not improve efficacy. Relative to BEV or ATE(+/-ASA) arms, the BEV+ATE combinations numerically improved PFS and TFST and merits further exploration. Translational analyses are ongoing to identify biomarkers of clinical benefit.



Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study.

Colombo, et al.


INTERMITTENT RELA + nab-pac improved PFS and had a favorable safety profile in recurrent platinum-resistant and/or platinum-refractory ovarian cancer patients.


Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

N. Colombo and Others



Randomised Phase II Trial of Olaparib compared to weekly paclitaxel or Olaparib plus Cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)

Nicum, et al.


The OCTOVA trial demonstrated that the combination of O+C showed greater efficacy than O alone, but we did not find evidence that wP was inferior to O in women with multiply relapsed OC.



Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Pujade-Lauraine, et al.


The OReO/ENGOT Ov-38 trial is the first to provide data on PARPi rechallenge in PSR OC pts. The trial met its primary PFS endpoint. Maintenance O provided a significant improvement in PFS vs P, irrespective of BRCAm status. A proportion of pts derived clinically relevant long-term benefit. Safety was consistent with the known profile of O.